CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 62 filers reported holding CARDIFF ONCOLOGY INC in Q4 2022. The put-call ratio across all filers is 19.84 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,227 | -6.7% | 71,386 | -1.4% | 0.00% | – |
| Q2 2023 | $106,407 | -8.4% | 72,386 | +2.8% | 0.00% | – |
| Q1 2023 | $116,198 | +19.6% | 70,423 | +1.5% | 0.00% | – |
| Q4 2022 | $97,138 | -9.2% | 69,384 | 0.0% | 0.00% | – |
| Q3 2022 | $107,000 | -27.2% | 69,384 | +4.2% | 0.00% | – |
| Q2 2022 | $147,000 | -81.3% | 66,592 | -79.0% | 0.00% | – |
| Q1 2022 | $788,000 | -61.3% | 317,858 | -6.3% | 0.00% | – |
| Q4 2021 | $2,038,000 | -5.5% | 339,081 | +4.7% | 0.00% | – |
| Q3 2021 | $2,156,000 | +2.0% | 323,706 | +1.8% | 0.00% | – |
| Q2 2021 | $2,114,000 | +390.5% | 317,845 | +582.1% | 0.00% | – |
| Q1 2021 | $431,000 | -46.2% | 46,597 | +4.7% | 0.00% | – |
| Q4 2020 | $801,000 | +127.6% | 44,520 | +79.4% | 0.00% | – |
| Q3 2020 | $352,000 | +517.5% | 24,817 | +118.8% | 0.00% | – |
| Q2 2020 | $57,000 | – | 11,342 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,522,083 | $16,797,000 | 13.61% |
| Octagon Capital Advisors LP | 982,753 | $6,545,000 | 1.61% |
| Altium Capital Management LP | 348,888 | $2,324,000 | 0.61% |
| ACT CAPITAL MANAGEMENT, LLC | 102,500 | $683,000 | 0.35% |
| Eventide Asset Management | 1,670,399 | $11,125,000 | 0.15% |
| Artal Group S.A. | 750,000 | $4,995,000 | 0.11% |
| Virtus ETF Advisers LLC | 25,770 | $172,000 | 0.08% |
| HighVista Strategies LLC | 15,501 | $103,000 | 0.07% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 13,500 | $90,000 | 0.05% |
| SCHOLTZ & COMPANY, LLC | 16,625 | $111,000 | 0.04% |